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Dengue viruses (DENV) are the most important arboviral pathogens in tropical and subtropical regions throughout the world. DENV
transmission includes both a sylvatic, enzootic cycle between nonhuman primates and arboreal mosquitoes of the genus Aedes, and an urban,
endemic/epidemic cycle between Aedes aegypti, a mosquito with larval development in peridomestic water containers, and human reservoir hosts.
All 4 serotypes of endemic DENV evolved independently from ancestral sylvatic viruses and have become both ecologically and evolutionarily
distinct; this process may have involved adaptation to (i) peridomestic mosquito vectors and/or (ii) human reservoir hosts. To test the latter
hypothesis, we assessed the ability of sylvatic and endemic DENV-2 strains, representing major genotypes from Southeast Asia, West Africa and
the Americas, to replicate in two surrogate human model hosts: monocyte-derived, human dendritic cells (moDCs), and mice engrafted with
human hepatoma cells. Although the various DENV-2 strains showed significant inter-strain variation in mean replication titers in both models, no
overall difference between sylvatic and endemic strains was detected in either model. Our findings suggest that emergence of endemic DENV
strains from ancestral sylvatic strains may not have required adaptation to replicate more efficiently in human reservoir hosts, implying that the
potential for re-emergence of sylvatic dengue strains into the endemic cycle is high. The shared replication profiles of the American endemic and
sylvatic strains suggest that American strains have maintained or regained the ancestral phenotype.
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immune deficiency (SCID) mouseIntroduction
The four serotypes of dengue virus (DENV) are transmitted
among humans by Aedes aegypti and Aedes albopictus
mosquitoes (Gubler, 1998), causing approximately 100 million
infections leading to dengue fever (DF) annually, and up to
500,000 cases of dengue hemorrhagic fever (DHF) with a case
fatality rate of up to 5% (Halstead, 1997). DENV is believed to
have evolved as a nonhuman primate virus transmitted by
canopy-dwelling arboreal mosquitoes before diverging into the 4
antigenically distinct DENV serotypes (DENV-1 to DENV-4),
each of which later emerged into the human population (Cheong,⁎ Corresponding author. Fax: +1 409 747 2455.
E-mail address: sweaver@utmb.edu (S.C. Weaver).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.08.0491986; Smith, 1956). Wang et al. (2000) tested this hypothesis
using phylogenetic analyses to compare envelope protein gene
sequences of the of endemic (human and Ae. aegypti) isolates to
sequences of sylvatic (nonhuman primate and arboreal Aedes
spp.) DENV-1, -2 and -4 strains of Southeast Asian origin, as well
as DENV-2 sylvatic strains from West Africa. These analyses
indicated that endemic DENV-1, -2 and -4 emerged indepen-
dently from sylvatic progenitors at a time consistent with the
establishment of urban populations in the Asia-Oceania region
large enough to support a continuous human transmission cycle
(Kuno, 1995). The Asiatic origin of DENV sylvatic progenitors is
further supported by serological surveys of ecologically diverse
rural habitats in Southeast Asia (Smith, 1956). More recently, the
global spread of dengue has given rise to distinct endemic
genotypes within each serotype (Gubler, 1997).
403N. Vasilakis et al. / Virology 358 (2007) 402–412Currently, transmission of DENVoccurs in 2 distinct cycles: a
sylvatic, enzootic cycle between nonhuman primates and treehole
mosquitoes of the genus Aedes (Diallo et al., 2003; Rudnick et al.,
1967), and an endemic cycle between humans and the
peridomestic mosquitoes Ae. aegypti and Ae. albopictus. In
rural areas of Africa and Asia (also known as the ‘zone of
emergence’) where mosquito vectors often reach high densities,
DENV strains could potentially transfer between the two cycles,
thus setting the stage for a re-emergence of the sylvatic strains
(Gubler, 1988). To anticipate and potentially prevent re-emer-
gence, it is critical to characterize the adaptations that would
enable sylvatic DENV to transmit efficiently among humans.
The present study focused on the DENV-2 serotype, which
has been grouped into five genotypes (Shurtleff et al., 2001)
based on phylogenetic relationships among the envelope protein
(E) gene sequences (Chang et al., 1994; Rico-Hesse, 1990;
Wang et al., 2000). Sylvatic DENV-2, which circulates in both
West Africa and Southeast Asia, shows a broader geographic
range than the remaining sylvatic serotypes, which have only
been detected in Southeast Asia. There is no evidence that the
sylvatic cycles are involved in outbreaks of human dengue,
suggesting that these strains are confined to forest habitats and/or
produce relatively mild human disease. While transmission of
sylvatic DENV-2 strains to humans has been documented in
several West African cases of dengue fever (Saluzzo et al., 1986;
Zeller et al., 1992), there is no evidence that sylvatic DENV
strains of any serotype have subsequently been transmitted
among humans to generate outbreaks (Diallo et al., 2003; Rico-
Hesse, 1990). Moreover, sylvatic DENV strains have not been
detected in the peridomestic vectors of endemic dengue,
suggesting that these strains are confined to forest habitats.
We hypothesized that emergence of sylvatic DENV strains
into the endemic cycle may require adaptation to peridomestic
mosquito vectors and/or human hosts. Previous comparisons of
the infectivity of sylvatic and endemic DENV-2 strains for
urban anthropophilic Ae. aegypti and Ae. albopictus mosquito
vectors demonstrated an advantage for the endemic strain,
suggesting that adaptation to these mosquito species had
accompanied emergence (Moncayo et al., 2004). Moreover, aTable 1
History of DENV-2 strains utilized in this study
Strain Epidemiological
type a
Host Pass
1349 Endemic Human SM2
16681 Endemic Human BSC
Tx. A
LLC
1328 Endemic Human Mos
IQT-1950 Endemic Human C6/3
PM33974 Sylvatic Ae. africanus Tx. A
P8-1407 Sylvatic Sentinel monkey SM3
A510 Sylvatic Ae. taylori SM4
A1247 Sylvatic Ae. taylori SM5
2022 Sylvatic Ae. africanus SM6
2039 Sylvatic Human SM6
a Endemic denotes human or Ae. aegypti isolates or strains that are associated wit
b SM—Suckling mouse; C6/36—Ae. albopictus cell line; LLC-MK2—Rhesus mcluster of amino acid changes in domain 3 of the viral envelope
protein, which is believed to interact with cellular receptors,
accompanied DENVemergence (Rico-Hesse, 1990; Wittke et al.,
2002), and amino acid substitutions in the envelope glycoprotein
of other arboviruses have been implicated in adaptation to novel
mosquito vectors (Brault et al., 2004).
In the current study, we compared the human infection
phenotypes of endemic and sylvatic DENV-2 strains using in
vitro and in vivo models to determine whether adaptation to
humans is a necessary component of dengue emergence. We
selected virus strains of relatively low passage histories that
represent all major DENV-2 genotypes, including both
African and Asian sylvatic strains, and Asian, African and
American endemic strains (Table 1). Both Asian and
American endemic strains were tested because they are
reported to differ in their human virulence (Cologna and
Rico-Hesse, 2003; Vaughn et al., 2000).
Because no animal model has been identified that recapitu-
lates human infection and disease, we utilized two surrogate
human models to compare the viremia and replication profiles
of sylvatic versus endemic strains: (1) monocyte-derived
dendritic cells (moDCs) from healthy volunteers (Wu et al.,
2000), and (2) the severe combined immune deficiency (SCID)
mouse xenografted with human hepatoma cells (An et al.,
1999). Although the DENV-2 strains showed significant
variation in mean replication titers, no overall difference
between sylvatic and endemic strains was detected in either
model. These findings suggest that emergence of endemic
DENV strains from ancestral sylvatic strains may not have
required adaptation to replicate more efficiently in humans as
reservoir hosts, implying that the probability of re-emergence of
human-to-human transmission is high.
Results
Phylogenetic analyses
We expanded previous phylogenetic analyses (Holmes and
Twiddy, 2003; Rico-Hesse, 1990; Wang et al., 2000) of theage history b Location Year
, C6/36-2 Burkina Faso 1982
-1–x, LLC-MK2-6, Rh. Macaque-1,
mboinensis -2, C6/36-4,
-MK2-1, C6/36-1
Thailand 1964
q.-2, C6/36-1 Puerto Rico 1977
6-2 Peru 1995
mboinensis -1, C6/36-2 Guinea 1981
, C6/36-2 Malaysia 1970
, C6/36-2 Ivory Coast 1980
, C6/36-1 Ivory Coast 1980
, C6/36-1 Burkina Faso 1980
, C6/36-1 Burkina Faso 1980
h peridomestic transmission.
onkey kidney cells; BSC-1—African green monkey kidney cells.
404 N. Vasilakis et al. / Virology 358 (2007) 402–412evolutionary relationships among endemic serotypes and their
sylvatic progenitors by using additional endemic and sylvatic
strains in the phylogeny. The sylvatic strains were isolated
between 1970 and 1981 in West Africa and Southeast Asia,
whereas the endemic strains were isolated between 1964 and
1995, in West Africa, South America and Southeast Asia (Table
1). Analysis of 1485 nucleotides encoding the envelope protein
(E) gene from 55 DENV-2 isolates, representing strains from
diverse localities throughout the tropics and neotropics,
included homologous DENV-1 and DENV-3 sequences as an
outgroup to root the DENV-2 tree. All phylogenetic methods
revealed 5 major DENV-2 lineages or genotypes, as has been
demonstrated in previous studies (Holmes and Twiddy, 2003;
Twiddy et al., 2002; Wang et al., 2000). The trees also revealedFig. 1. Phylogenetic analysis of DENV isolates. Phylogenetic tree derived from the en
DENV-2 strains using Bayesian analysis or maximum likelihood (ML) (PAUP, vers
approximation method. The following ML parameters corresponding to the GTR+G
C=0.19737, G=0.25924 and T=0.21350); and among-site rate variation as: at inva
variable sites. The scale shows a genetic distance of 0.01 or 1% nucleotide sequence
used as an outgroup to root the DENV-2 tree. Numbers indicate bootstrap values foconsiderable genetic diversity within the DENV-2 genotypes,
reflecting their continual divergence and diverse geographic
distribution. Representative members of the major genotypes
(Fig. 1) were selected for experimental studies.
All sylvatic DENV-2 isolates from Malaysia and West Africa
were genetically distinct from endemic DENV-2 isolates. The
endemic DENV-2 strains showed further subdivisions between
the American and Asian lineages, with high bootstrap support
using Bayesian and/or maximum parsimony methods, consis-
tent with previous reports (Holmes and Twiddy, 2003; Twiddy
et al., 2002; Wang et al., 2000). The Asian lineage included
isolates clustered in 3 groups, Asian, American/Asian and
Cosmopolitan, with bootstrap support of 71%, 100% and 99%
respectively (Fig. 1).velope protein gene nucleotide sequences of sylvatic and representative endemic
ion 4.10) and drawn using branch lengths obtained using the Rogers–Swofford
+I model were used: empirical values for nucleotide frequencies (A=0.32989,
riable sites as estimated and γ distribution (discrete approximation) of rates at
divergence. Homologous sequences from dengue sister serotypes 1 and 3 were
r groups to the right. Asterisks indicate the strains used for this study.
Table 2
Serum viremia of endemic and sylvatic DENV-2 in vivo
Virus a Epidemiological
type
No. of
mice b
Mean peak virus titer c, d
(log10 ffu/ml±SE)
Statistical
group e
16681 Asian endemic 7 5.9±0.2 A
1349 Asian endemic 6 4.9±0.3 B, C
1328 American
endemic
6 2.9±0.3 D
IQT-1950 American
endemic
6 4.0±0.3 C, E
P8-1407 Sylvatic 7 5.4±0.2 A, B
PM33974 Sylvatic 6 3.6±0.2 D, E
a Groups of 10 SCID-Huh-7 mice were inoculated into the tumor with 4.0–4.2
log10 ffu of the indicated virus. Serum was collected on day 7 and virus titer was
determined on C6/36 cells.
b Mice that failed to develop viremia were excluded from the experiments.
c Virus titer in serum was determined by FFA in C6/36 cells.
d The limit of detection of the assay is 0.5 ffu/ml.
e Mean peak titers were assigned to statistical groups using the Tukey–Kramer
post hoc test. Groups sharing at least one letter are not significantly different;
groups not sharing any letter are significantly different (P<0.05).
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A major limitation in dengue research is the lack of an
inexpensive laboratory animal model that recapitulates human
disease and viremia. A large number of nonhuman primates
support DENV replication without developing clinical signs of
illness (Halstead et al., 1973; Rosen, 1958). Nevertheless,
because the duration and magnitude of virus replication in
nonhuman primates often correlates with patterns of replica-
tion in humans, primates have become the gold standard for
evaluation of live attenuated dengue vaccine candidates
(Angsubhakorn et al., 1988; Blaney et al., 2005; Edelman et
al., 1994; Hanley et al., 2004; Markoff et al., 2002; Men et al.,
1996; Robert Putnak et al., 2005). However, economic and
animal facility limitations preclude widespread utility of
nonhuman primates as a useful model for DENV replication.
Several murine models (Boonpucknavig et al., 1981; Chatur-
vedi et al., 1991; Cole and Wisseman, 1969; Hotta et al.,
1981) developed to evaluate protective immune responses,
have proven to be ineffective due to the absence of DENV
replication and illness or the requirement for murine-adapted
DENV (Cole and Wisseman, 1969; Sabin, 1952). Human
peripheral blood lymphocytes (hu-PBL) engrafted in SCID
mice (Wu et al., 1995) infected with DENV produce high
viremia and virus loads in the spleen and lymph nodes.
Limitations of this model include extensive labor requirements
and variable reconstitution (successful engraftment) rates.
Observations documenting hepatic lesions (Couvelard et al.,
1999; Lum et al., 1993), as well as detection of DENV antigen
in hepatocytes (Kuo et al., 1992) during human infections
formed the rationale for development of the SCID-xenograft
model, where human hepatoma cells (HepG2 or Huh-7) are
grafted intraperitoneally (i.p.) into SCID mice and DENV is
injected directly into the i.p. tumor (An et al., 1999; Blaney et
al., 2002). Mice develop gradual illness with peak viremia on
day 7, whereas peak viral replication in the liver is detected by
day 5 with gradual declines, and by day 11 virus has reached
peak titers in the brain. This pattern of replication is similar to
that which accompanies human infection, where DENV
initially replicates at the site of infection and gradually
disseminates to other organs and to the brain (although cerebral
involvement is not believed to be common in human infections)
via the circulation (Rothman, 1997). These are the first animal
models where DHF/DSS-like manifestations (gastrointestinal
bleeding and small focal hemorrhages in the livers of some
mice) similar to those seen in human infections (Burke, 1968;
Rosen et al., 1989) occur, and have proved useful for virulence
testing of DENV vaccine candidates (Blaney et al., 2002;
Whitehead et al., 2003). More recently, a humanized mouse
model based on the grafting of human CD34+ cells in nonobese
diabetic/severely compromised immunodeficient mice (NOD/
SCID), has also been proposed as a model for studying the
pathogenicity of DENV infection (Bente et al., 2005).
However, based on the consistency of the SCID-Huh-7
xenograft model in evaluating the virulence of DENV vaccine
candidates, we selected this model for the in vivo evaluation of
our hypothesis.To assess the human infection phenotypes of sylvatic versus
endemic DENV-2 strains and to determine statistically dictated
cohort numbers and tumor development efficiency, we
conducted a pilot experiment using the Asian endemic 1349
and sylvatic PM33974 strains. The sylvatic strain generated
moderate peak viremia levels of 4 log10ffu/ml (N=3), while
the endemic strain generated significantly higher viremia of 6
log10ffu/ml on day 7 (N=7) (t-test, df=7, t=4.49, P<0.002)
(data not shown). We also bled the mice at days 2, 4 and 7
post-infection (p.i.), and mean replication titers consistently
peaked at day 7 p.i. (data not shown) as described earlier (An
et al., 1999; Blaney et al., 2002). Power analyses indicated that
a minimum of 6 animals per group were required to detect
significant differences (P=0.861, α=0.05), with tumor
development efficiency at 88%. Therefore, to compare the
sylvatic versus endemic human infection phenotypes, six
groups of 10 SCID-huh7 mice were infected with one of 2
sylvatic (PM33974, P8-1407) or 4 endemic (Asian 1349 and
16681, and American IQT-1950 and 1328) DENV-2 strains
(Fig. 1). A significant overall difference among the mean
serum titers of the six strains was detected (one-way ANOVA,
P<0.0001) and a Tukey-Kramer post hoc test revealed
multiple significant differences among individual pairs of
strains (Table 2). However, this complex pattern of differences
did not indicate a consistent or overall difference between
sylvatic and endemic strains or between Asian endemic and
American endemic strains. For example, the titer of Asian
endemic strain 16681 was significantly higher than any of the
other three endemic strains but not significantly different from
sylvatic strain P8-1407.
Replication of sylvatic and endemic DENV-2 strains ex vivo
Natural DENV infection involves virus deposition in the skin
by the mosquito vector during blood feeding. Blood and
resident skin dendritic cells (DC) including Langerhans cells
406 N. Vasilakis et al. / Virology 358 (2007) 402–412(LC) may be the initial target of viral infection following
exposure toDENVduring injectionofmosquito saliva (Marovich
et al., 2001; Wu et al., 2000). DCs efficiently take up pathogens
through phagocytocis, pinocytosis and receptor-mediated endo-
cytosis. The latter is mediated through lectins (i.e. CD209, DC-
SIGN) (Navarro-Sanchez et al., 2003; Tassaneetrithep et al.,
2003), as well as immunoglobulin Fc receptors. DENV-infected
DCs then migrate to the lymphoid tissues through the afferent
lymphatic system, where they mature and interact with T-cells
(Austynetal.,1988;Steinman,1991),andcouldshedvirus,aiding
in dissemination.
Because of the great genetic diversity of the human popu-
lation at risk as well as epidemiologic evidence suggesting the
influence of host genetics in the development of DENV viremia
and disease (Bravo et al., 1987), we utilized moDC from
anonymous, healthy donors of Caucasian, West African and
Southeast Asian origin (3 donors per ethnic group) to assess the
human infection phenotypes of 2 sylvatic (PM33974, P8-1407)
and 4 endemic (Asian 1349 and 16681, and American IQT-1950
and 1328) DENV-2 strains. Prior to infection, the immature
moDC phenotype was confirmed with a panel of fluorescein-
isothiocyanate (FITC)-conjugated monoclonal antibodies
against common DC markers, CD40, CD80, CD83, CD86
and DC-specific ICAM-3 grabbing non-integrin (DC-SIGN)
using a FACScan flow cytometer (Fig. 2A). DC-SIGN is not a
marker of the moDC phenotype, but mediates the infection of
human DCs by DENV (Tassaneetrithep et al., 2003). ImmatureFig. 2. FACS analysis of blood-derived DCs. (A) Cell surface staining of immature b
cocktail prior to DENV-1349 infection and infected blood-derived DCs at day 2 pos
and DC-SIGN was evaluated to determine the maturity of the DCs immediately prior
the infection of human DCs by DENV. Green peaks, isotype control; purple-shaded
representative of three independent experiments. (B) Infected DCs were examined b
followed by an FITC-conjugated secondary antibody to determine the percentage of
and error bars represent the standard errors of the means.moDCs are susceptible to DENV infection, whereas mature
moDCs are refractory (Wu et al., 2000). The moDC infection
rates determined by FACS analysis varied between 6.4% and
18% (Fig. 2B). We also observed interdonor variation among
the levels of moDC infections (data not shown), which was
within the range of variation described in previous reports of
DENV infection of human moDCs (Cologna et al., 2005;
Sanchez et al., 2006). The cell-free supernatants of the infected
moDCs were collected at 24 and 48 h post-infection and viral
output was evaluated by focus forming assay (FFA) on C6/36
cells. Mean replication titers peaked consistently at 48 h post-
infection (Tables 3 and 4), as observed in previous reports
(Palmer et al., 2005; Wu et al., 2000). As illustrated in Table 3,
the 6 DENV-2 isolates showed significant differences in levels
of replication (df=5, F=69.9, P<0.0001); endemic Asian
strains consistently generated higher virus outputs than the
American DENV-2 strains, as demonstrated previously
(Cologna et al., 2005), as well as the sylvatic DENV-2 isolates
(Tukey-Kramer post hoc test, P<0.05). However, no consistent
difference between endemic American and sylvatic DENV-2
replication was detected. One of the 2 sylvatic strains, African
PM33974, failed to replicate in the moDCs of all but one donor
(the limit of detection of FFA assay was 0.5 log10 ffu/ml) (data
not shown). To eliminate the possibility that this strain was an
abberant outlier, possibly due to artificial selection during its
passage history, 4 additional African sylvatic strains (Table 1)
were evaluated in moDCs from 2 human volunteers. The poorlood-derived moDCs at day 6 post stimulation with IL-4 and GM-CSF cytokine
t-infection with DENV-1349. Surface expression of CD40, CD80, CD83, CD86
to DENV infection. DC-SIGN is not a marker of moDC phenotype but mediates
peaks, non-infected immature DCs; pink peaks, infected mature DCs. Data are
y FACS analysis 48 h post-infection with an α-dengue virus-specific antibody,
infected cells. Graph represents pooled data generated from 2 individual donors
Table 4
Replication profile of expanded endemic and sylvatic DENV-2 ex vivo
Virus a Epidemiological type Mean peak virus titer b, c, d
(log10 ffu/ml±SE)
Statistical
group e
16681 Asian endemic 5.4±0.1 A
1349 Asian endemic 5.0±0.3 A
1328 American
endemic
3.1±0.6 B
IQT-1950 American
endemic
4.3±0.2 B
P8-1407 Sylvatic 3.2±0.0 B
PM33974 Sylvatic 0.5±0.0 C
A510 Sylvatic 4.4±0.2 B
A1247 Sylvatic 0.5±0.0 C
2022 Sylvatic 2.6±0.1 B
2039 Sylvatic 4.6±0.2 B
a moDCs (2.5×105 per sample) from two healthy human volunteers were
infected with an MOI=2 of the indicated virus. Supernatants were collected
48 h p.i. and viral output was determined on C6/36 cells.
b Virus titer in serum was determined by FFA in C6/36 cells.
c The limit of detection of the assay is 0.5 log10 ffu/ml.
d Data represent two individual experiments pooled together.
e Mean peak titers were assigned to statistical groups using the Tukey–Kramer
post hoc test. Groups sharing at least one letter are not significantly different;
groups not sharing any letter are significantly different (P<0.05).
Table 3
Replication profile of endemic and sylvatic DENV-2 ex vivo
Virus a Epidemiological type Mean peak
virus titer b, c, d
(log10 ffu/ml±SE)
Statistical
group e
16681 Asian endemic 4.8±0.1 A
1349 Asian endemic 5.3±0.2 A
1328 American endemic 2.7±0.3 B
IQT-1950 American endemic 3.3±0.4 B
P8-1407 Sylvatic 3.1±0.2 B
PM33974 Sylvatic 0.6±0.1 C
a moDCs (2.5×105 per sample) from nine healthy human volunteers were
infected individually with an MOI=2 of the indicated virus. Supernatants were
collected 48 h p.i. and viral output was determined on C6/36 cells.
b Virus titer in serum was determined by FFA in C6/36 cells.
c The limit of detection of the assay is 0.5 log10 ffu/ml.
d Data represent nine individual experiments pooled together.
e Mean ex vivo peak titers were assigned to statistical groups using the
Tukey–Kramer post hoc test. Groups sharing at least one letter are not
significantly different; groups not sharing any letter are significantly different
(P<0.05).
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sylvatic A1247 strain, but not by the other 3 sylvatic strains
analyzed (Table 4). As in the previous analyses, all of these
sylvatic strains replicated to lower titers than the endemic Asian
strains, but did not differ consistently from the endemic
American strains (Tukey-Kramer post hoc test, Table 4). A
comparison of the mean titers of endemic (N=4) and sylvatic
(N=6) strains showed no consistent difference in the mean level
of replication of this expanded group of sylvatic DENV-2
strains compared to the endemic isolates (Student's t-test:
df=8; t=1.35; P=0.21).
Discussion
The presence of neutralizing antibodies in canopy-dwelling
nonhuman primates (Rodhain, 1991; Rudnick, 1986; Smith,
1956; Wolfe et al., 2001), the relatively recent development of
large, concentrated human populations in the zone of emergence
and phylogenetic (Wang et al., 2000) evidence suggest that
sylvatic DENV strains are the ancestors of the existing endemic
DENV strains that circulate in most of the tropics, putting a
third of the global human population at risk and causing a huge
burden of morbidity and mortality. These sylvatic DENV are
maintained in enzootic cycles between forest-dwelling Aedes
spp. mosquito vectors (not Ae. aegypti or Ae. albopictus) and
probably nonhuman primate reservoir hosts in the sylvan
ecosystems of Southeast Asia (Rudnick, 1986) and West Africa
(Saluzzo et al., 1986; Traore-Lamizana et al., 1994).
Endemic dengue viruses are believed to have originated from
ancestral sylvatic strains that switched from arboreal to urban
mosquito vectors and from nonhuman primate to human
reservoir hosts. Assessing the likelihood of current sylvatic
DENV strains to undergo a similar emergence is important for
public health. Specifically, programs to reduce or eradicate
dengue from human populations by vector control or vaccina-
tion might be short-lived if sylvatic DENV strains can readily
re-emerge from sylvatic cycles not amenable to intervention.The success of these programs could hinge on sustainable
vaccination coverage of the susceptible population at risk and/or
virtual elimination of endemic vector mosquitoes. Active
employment of these methods should prevent the successful
introduction of sylvatic DENV into the urban cycle and thus
eliminate the resurgence of a major public health problem.
Nevertheless, if the endemic DENV transmission cycle is
eradicated as the result of public health measures, cessation of
the anti-dengue campaigns (vaccination and/or vector control) for
a sufficiently long time will lead to the rise of susceptible human
populations, as well as the establishment of adequate populations
of endemic vector mosquitoes. Under such conditions, the re-
emergence of human replication competent disease-producing
sylvatic DENV could pose a problem to human health.
Information critical to assessing the potential for re-emergence
includes: (1) the ability of humans to serve as reservoir hosts for
sylvatic DENV strains with or without adaptation; (2) the degree
of ecological contact between humans and sylvatic DENV
strains; (3) ability of peridomestic mosquitoes to serve as vectors
for sylvatic DENV transmission; and (4) the ability of the sylvatic
strains to evolve to efficiently complete a transmission cycle in
human hosts and peridomestic vectors.
Collectively, our findings do not support the hypothesis that
emergence of endemic DENV strains involved adaptation to
human reservoir hosts. The endemic strains we tested did not
produce higher viremia in the mouse model or higher levels of
DENV-2 replication in dendritic cells, compared to sylvatic
strains. Assuming that the phenotype of the extant sylvatic
strains is ancestral, this suggests that emergence of endemic
DENV-2 strains from sylvatic strains did not require adaptation
to replicate more efficiently in human reservoir hosts. Our data
therefore imply that re-emergence of human-to-human trans-
mission may occur readily. Comparable studies with DENV-1
408 N. Vasilakis et al. / Virology 358 (2007) 402–412and -4 strains [sylvatic DENV-3 strains have not been isolated
but are believed to exist in Malaysia based on the seroconver-
sion of sentinel monkeys (Rudnick, 1978)] are needed to
determine if the other sylvatic DENV strains are also capable of
efficient human infection.
Data in the literature on disease severity in humans with
different racial backgrounds suggest that host genetics may
influence the outcome of DENV infection (Bravo et al., 1987;
Kouri et al., 1987). The utilization of the human surrogate animal
and human dendritic cell models allowed us to control for host
genetics to evaluate putative differences in the DENV-2
replication phenotypes among sylvatic and endemic strains.
The significant differences in the replication profiles of Southeast
Asian and American DENV strains observed in both models
support previous evidence for the higher pathogenic potential of
Southeast Asian strains (Cologna et al., 2005; Leitmeyer et al.,
1999; Watts et al., 1999). Although higher replication profiles in
vivo have been associated with severe disease (Vaughn et al.,
2000; Wang et al., 2003), other factors such as immune
enhancement (Halstead, 2003), genetic predisposition (Bravo
et al., 1987), gender and age (Guzman et al., 1984) and nutrition
(Thisyakorn and Nimmannitya, 1993) may influence the
pathogenic outcome to DENV infections. Moreover, although
ourmoDCswere obtained froma small number of humandonors,
they represented different ethnicity and no differences were
observed in their ability to support DENV-2 replication. Lastly,
without coming to conclusions about which was the first to
evolve, the shared replication profiles of the American endemic
and sylvatic strains suggest that American strains may have
“relaxed’ into the lower replication phenotype after evolution in
the Americas.
Twiddy et al. (2002) attempted to identify evidence of
positive selective pressure during the evolution of sylvatic and
human DENV strains, but found no evidence of adaptive
evolution in the E gene that coincided with the emergence of
endemic strains. Although the computational methods used to
identify positive selection have limitations, the lack of evidence
for selective pressure during endemic emergence would imply
that currently circulating sylvatic strains may not have difficulty
spreading into the human reservoir host should the appropriate
conditions occur. However, there is no evidence for the recent,
direct involvement of these enzootic strains in DENV
epidemics, which always involve genetically distinct endemic
strains. Nevertheless, in rural areas of Africa and in Asia where
the peridomestic Ae. albopictus mosquito vectors often reach
high densities, DENV may be transmitted at low frequency
from its sylvatic reservoir and humans. Additional ecological
studies are necessary to identify and assess the role of vertebrate
hosts in the maintenance and amplification of sylvatic DENV,
which may provide valuable insight to the degree of the
ecological contact between humans and sylvatic DENV. Ideally
infectivity and disease expression of these viruses should be
evaluated in human volunteers, but ethical or legal considera-
tions may preclude their evaluation in human volunteers.
However a comparison of the pattern of replication of sylvatic
and endemic viruses in nonhuman primates is certainly war-
ranted at this juncture. This information is needed to predict therisk of sylvatic DENV emergence and establishment of an
epidemic in humans.
Materials and methods
Cell cultures and viruses
C6/36 (mosquito, Ae. albopictus) cells were maintained in
Eagle's minimal essential medium (MEM) supplemented with
5% fetal bovine serum (FBS), 50 mg/ml penicillin/streptomycin,
2 mM L-glutamine and non-essential amino acids (NEAA)
(Invitrogen, Carlsbad) at 28 °C. Human hepatoma Huh-7 cells
(clone JTC-39) were obtained from the Japanese Health
Sciences Foundation, Osaka and were maintained in Dulbecco's
MEM supplemented with 10% FBS, 50 mg/ml penicillin/
streptomycin and 2 mM L-glutamine. DENV-2 isolates with the
lowest in vitro passage histories (Table 1) were selected from the
World Reference Center for Emerging Viruses and Arboviruses,
University of Texas Medical Branch to reduce the chance of cell
culture or mouse adaptive mutations. Viral isolates were
passaged twice in C6/36 cultures to obtain high titer stocks.
Supernatants were clarified from cellular debris by low-spin
centrifugation (630×g, 20min, 4 °C) stabilizedwith the addition
of 10× SPG (2.18 M Sucrose, 0.038 M KH2PO4, 0.072 M
K2HPO4 and 0.054 M L-glutamate), and stored at −80 °C.
Focus forming assays (FFA) and immunostaining
Ten-fold serial dilutions of virus were added to confluent
C6/36 cell monolayers. The virus inoculum was removed 1
h later, cell monolayers were washed and overlayed with 0.8%
methylcellulose (Sigma-Aldrich, St. Louis) diluted in Optimem
(Invitrogen, Carlsbad) supplemented with 2% FBS, antibiotics,
1% L-glutamine and 1% NEAA. Plates were incubated for 4
days at 28 °C, the methylcellulose overlay was removed and
plates were rinsed with phosphate-buffered saline (PBS), pH
7.4. Plates were fixed with the addition of ice-cold acetone and
methanol (1:1) for 30 min at room temperature (RT). The
fixation solution was aspirated and plates were allowed to air
dry. Plates were then washed with PBS, followed by blocking
(PBS supplemented with 3% FBS) and addition of mouse anti-
DENV-2 ascites fluid (1:1000) and incubation for 30 min. The
antibody was aspirated and plates washed 3 times in PBS
followed by addition of secondary antibody conjugated to
horseradish peroxidase (HRP) (KPL, Gaithersburg) (1:1000)
and incubation at RT for 30 min. Plates were washed 3 times
with PBS and aminoethylcarbazole (AEC) substrate (ENZO
Diagnostics, Farmingdale), prepared according to the manufac-
turer's instructions, was added and allowed to incubate in the
dark for 10 min. Substrate solution was aspirated, washed with
water and plates were allowed to air dry before scoring.
Isolation, stimulation of peripheral blood mononuclear cells
and DENV infections of moDCs
Nine consenting healthy volunteers, with no history of
infection to any of DENV serotypes and confirmed as negative
409N. Vasilakis et al. / Virology 358 (2007) 402–412by plaque reduction neutralization test (PRNT) assay, were used
to obtain approximately 100 ml of blood. Peripheral blood
mononuclear cells were then isolated from buffy coats by
centrifugation over an Accuprep gradient according to the
manufacturer's protocol (Accurate Chemical Corp, Westbury).
CD14+ monocytes were positively selected using amagnetic cell
sorting (MACS) isolation column (Miltenyi Biotec, Auburn).
Cells were counted and seeded in 6-well plates at a density of
1–2×106 cells per well in RPMI 1640 culture medium
supplemented with 10% heat-inactivated FBS, 100 U/ml
penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine,
containing 1000 U/ml recombinant human interleukin 4 (IL-4)
(R&D Systems, Minneapolis) and 1400 U/ml granulocyte–
monocyte colony-stimulating factor (Immunex, Thousand
Oaks). On alternate days, one-half of the volume was removed
and replaced with medium containing double (2×) the
concentration of fresh cytokines. Cultures were maintained
under these conditions for a total of 6 days, then cells were
collected with gentle pipetting, washed and the moDC
phenotype was confirmed by FACS analysis using a panel of
FITC-conjugated monoclonal antibodies against CD40, CD80,
CD83, CD86 and DC-SIGN. Subsequently, 1×105 cells were
infected with the selected DENV at MOI=2 for 2 h at 37 °C.
The virus inoculum was removed and the cells were washed 3
times with PBS to ensure removal of unadsorbed virus. Cells
were resuspended in 2 ml of RPMI 1640 culture medium
supplemented with cytokines and incubated at 37 °C. Cell-free
supernatant aliquots were removed immediately prior and after
infection, at day one and two post-infection and were assayed
on C6/36 cells to obtain infection and progeny titers
respectively. moDC infection rates were established by FACS
analysis using a DENV-specific antibody (7E11, courtesy of
Dr. Putnak), as well as IHC on cell cytospins.
Flow cytometry
Uninfected and/or infected DCs were washed once in FACS
staining buffer (PBS containing 1% FBS) prior to confirmation
of their immature phenotype with a panel of FITC-conjugated
monoclonal antibodies against CD40, CD80, CD83, CD86,
DC-SIGN (Beckman-Coulter), as well as for intracellular
DENV antigen. As a control, the appropriate isotype was also
utilized. Cells were allowed to incubate on ice for 30 min
followed by washing twice with FACS staining buffer to
remove unbound antibody. Cells were then fixed in buffered 2%
paraformaldehyde (pH 9.5) and analyzed with a FACScan flow
cytometer (Becton Dickinson) within 24 h of staining. Prior to
fixation, cells that had been probed for DENV antigen were
subjected to secondary staining with FITC-conjugated antibody
(Molecular Probes) and washed twice with FACS staining
buffer.
SCID mice
Ten 5–6-week-old SCID mice (Tac:Icr:Ha[ICR]-Prkdcscid;
Taconic Farms) per group were xenografted intraperitoneally
(i.p.) with 1×107 Huh-7 cells suspended in 0.2 ml phosphate-buffered saline. Tumors were detected 5–6 weeks later by
palpation, and mice were infected by direct injection into the
tumor mass with 1×104 focus-forming units (ffu) of virus
diluted in 50 ml of PBS. Seven days post-infection, the mice
were sacrificed and blood was isolated by cardiac puncture and
the serum stored at −80 °C. Virus titers were determined by
FIA in C6/36 cells. Mice that failed to develop viremia were
excluded from the experiment. Prior to implantation, Huh-7
cells were certified to be free of mycoplasma, human and
mouse viruses using PCR or RT-PCR (Taconic Anmed,
Rockville). Animal experimentation was approved by the
UTMB IACUC and mice were maintained in gnotobiotic
isolators on specific pathogen-free environment.
Statistical analyses
GraphPad Prism version 4 software (GraphPad Software)
was used for data analyses. Virus outputs from 11 ex vivo or 2
in vivo experiments were grouped by virus strain and compared
by one-way ANOVA. The Tukey–Kramer post hoc test was
used to test for differences between pairs of strains. Student's
t-tests were used for two sample comparisons.
RNA extraction and sequencing
Viral RNA was extracted from virus preparations using the
QIAamp Viral RNAmini kit (Qiagen). PCR primers designed to
amplify the E protein gene (Wang et al., 2000) were used with
the Titan one step RT-PCR kit (Roche, Indianapolis). Viral RNA
was denatured for 2 min at 70 °C and cDNAwas synthesized at
50 °C for 30 min, followed by 35 rounds of amplification in a
50 μl reaction volume. The PCR products were purified from
1% agarose gels and both strands were sequenced directly using
an Applied Biosystems (Foster City, California) Prism auto-
mated DNA sequencing kit and model 3100 Genetic Analyzer
sequencer according to the manufacturer's protocol.
Phylogenetic analyses
The obtained nucleotide sequences encoding the envelope
(E) protein, and representative sequences from the GenBank
library, were aligned using the ClustalW multiple sequence
alignment program with default gap penalties. Phylogenetic
analyses of the aligned nucleotide sequences were performed
using Bayesian analysis with 1 million reiterations and/or
maximum likelihood, neighbor joining and maximum parsimo-
ny methods implemented in the PAUP 4.0 software package
(Swofford, 1998). Homologous nucleotide sequences from
DENV-1 and -3 were used as an outgroup to root the DENV-2
tree. Bootstrapping with 1000 replicates was used to place
confidence values on grouping within the tree (Felsenstein,
1985).
Nucleotide sequence accession numbers
The GenBank accession numbers for the DENV viruses used
in the phylogenetic analyses are as follows: for DENV-2 strain
410 N. Vasilakis et al. / Virology 358 (2007) 402–41240274, accession number L10041; 124B, AY158340; 49255,
AY577430; 6663, AY079424; 360236, AY158331; 360281,
AY577431; 102954, AY158330; 19966, AY577433; Mara3,
AY158329; Oax468, AY158341; 15957, AY577434; N.1409,
M20558; M56309, X15433; b87MS8455, X15434; ThNH-28,
U31950; ThNH-52, U31951; ThNH-7, U31959; ThNH-p11,
U31952; Puo-218, U87331; 16681, U87411; TH-36, D10514;
1897, L10052; 2088, L10045; NGC, AF038403; #10, L10051;
0190, L10042; 1051, L10044; S-44554, L10048; S-44552,
L10047; 1583, L10050; 1592, L10040; 271206, L10049;
206714, L10055; 271235, L10054; P7-863, AF231716; P8-
377, AF231715; PR158, L10046; 131, AY158332; 132,
AY158333; 328298, AY158338; Ven2, AY158328; IQT2133,
AY577439; IQT2913, AY158339; 780477, AY158327;
200787, L04561; P9122, L10043; TR1751, L10053; DAK
Ar578, AF231718; PM33974, AF231719; DAK HD10674,
AF231720; P8-1407, AF231717; D1/45A25, U88536; D1/836-
1, D00503; D1/CV1636, D00501; D1/AHF82, D00502; D1/
P72-1244, AF231721; D3/2783, L11438; D3/260698, L11437;
D3/5987, L11430; D3/D86-007, L11441; D3/CH3489D73-1,
L11620; H87, M93130; 29472, L11422; and 168-Ap-2,
L11432. The following sequences were determined in this
study: IQT-1950; 1328; A510; A1247; 2039 and 2022.
Nucleotide sequences were submitted to GenBank under
accession nos. DQ917242 to DQ917247.
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